These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 27130973

  • 21. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
    Lad EM, Hammill BG, Qualls LG, Wang F, Cousins SW, Curtis LH.
    Am J Ophthalmol; 2014 Sep; 158(3):537-43.e2. PubMed ID: 24857687
    [Abstract] [Full Text] [Related]

  • 22. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [Abstract] [Full Text] [Related]

  • 23. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R, Arora R, De Salvo G, Stinghe A, Severn PS, Pal B, Goverdhan S.
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [Abstract] [Full Text] [Related]

  • 24. Medicare costs for neovascular age-related macular degeneration, 1994-2007.
    Day S, Acquah K, Lee PP, Mruthyunjaya P, Sloan FA.
    Am J Ophthalmol; 2011 Dec; 152(6):1014-20. PubMed ID: 21843875
    [Abstract] [Full Text] [Related]

  • 25. One year follow-up of functional recovery in neovascular AMD during monthly anti-VEGF treatment.
    Munk MR, Kiss C, Huf W, Sulzbacher F, Roberts P, Mittermüller TJ, Sacu S, Simader C, Schmidt-Erfurth U.
    Am J Ophthalmol; 2013 Oct; 156(4):633-43. PubMed ID: 23891335
    [Abstract] [Full Text] [Related]

  • 26. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
    Shaikh AH, Toussaint BW, Miller DM, Petersen MR, Foster RE, Riemann CD, Hutchins RK, Sisk RA.
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
    [Abstract] [Full Text] [Related]

  • 27. Stereotactic radiotherapy for wet age-related macular degeneration (INTREPID): influence of baseline characteristics on clinical response.
    Jackson TL, Shusterman EM, Arnoldussen M, Chell E, Wang K, Moshfeghi DM, INTREPID Study Group.
    Retina; 2015 Feb; 35(2):194-204. PubMed ID: 25102198
    [Abstract] [Full Text] [Related]

  • 28. Radiation therapy: age-related macular degeneration.
    Mendez CA, Ehlers JP.
    Dev Ophthalmol; 2013 Feb; 52():75-84. PubMed ID: 23989128
    [Abstract] [Full Text] [Related]

  • 29. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
    Panchmatia HR, Clements KM, Hulbert E, Eriksson M, Wittrup-Jensen K, Nilsson J, Weinstein MC.
    Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
    [Abstract] [Full Text] [Related]

  • 30. 16 and 24 Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes.
    Morales-Canton V, Quiroz-Mercado H, Velez-Montoya R, Zavala-Ayala A, Moshfeghi AA, Shusterman EM, Kaiser PK, Sanislo SR, Gertner M, Moshfeghi DM.
    Am J Ophthalmol; 2013 Jun; 155(6):1000-1008.e2. PubMed ID: 23497847
    [Abstract] [Full Text] [Related]

  • 31. Patient perceptions and experiences of stereotactic radiotherapy for wet age-related macular degeneration.
    Senra H, Joseph S, Balaskas K, Horani M, Aslam T.
    Eur J Ophthalmol; 2016 Jun 10; 26(4):e80-2. PubMed ID: 26833232
    [Abstract] [Full Text] [Related]

  • 32. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
    Kim YJ, Sung KR, Lee KS, Joe SG, Lee JY, Kim JG, Yoon YH.
    Am J Ophthalmol; 2014 Jun 10; 157(6):1266-1271.e1. PubMed ID: 24561173
    [Abstract] [Full Text] [Related]

  • 33. Burden of Wet Age-Related Macular Degeneration and Its Economic Implications in Singapore in the Year 2030.
    Saxena N, George PP, Hoon HB, Han LT, Onn YS.
    Ophthalmic Epidemiol; 2016 Aug 10; 23(4):232-7. PubMed ID: 27340738
    [Abstract] [Full Text] [Related]

  • 34. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH, Dugel PU, Ferreira A, Hashmonay R, Lu J, Kelly SP.
    Ophthalmic Epidemiol; 2016 Aug 10; 23(2):71-9. PubMed ID: 26855278
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.
    Klin Monbl Augenheilkd; 2007 Sep 10; 224(9):727-32. PubMed ID: 17846963
    [Abstract] [Full Text] [Related]

  • 38. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC, Suñer IJ, Hammer ME, Grizzard WS.
    Ophthalmology; 2015 Apr 10; 122(4):803-8. PubMed ID: 25596618
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Retinal Ganglion Cell Layer Change in Patients Treated With Anti-Vascular Endothelial Growth Factor for Neovascular Age-related Macular Degeneration.
    Beck M, Munk MR, Ebneter A, Wolf S, Zinkernagel MS.
    Am J Ophthalmol; 2016 Jul 10; 167():10-7. PubMed ID: 27084000
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.